NEW YORK (GenomeWeb) – London-based startup My Personal Therapeutics (MPT) has developed a targeted therapeutic recommendation platform based on whole-exome sequencing data and fruit fly "avatars," which it said will hopefully minimize the amount of toxic drugs needed during treatment.
The firm now plans to commercialize a personalized treatment advisory service based on the platform called "TuMatch" for cancer patients, starting with colorectal cancer (CRC), by the end of the year.